Belinda A. Campbell

department of medicine university of melbourne melbourne victoria australia

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (3)

Geoff Delaney

Head of the Cancer Clinical Academic Group

MSG Sphere

AUSTRALIA

View details

Tomas Kron

University of Wollongong

AUSTRALIA

View details

Martine Bagot

Prof and Head

Université Paris-Saclay

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Belinda A. Campbell

Research Interests

Explore related searches

Contact this professor

Articles (10)

Radiation Therapy Utilization for Primary Cutaneous T-Cell Lymphoma Is Lowest Among Patients Living in the Most Geographically Accessible Areas: An Australian Study

Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes

Geospatial analyses demonstrate variation of cutaneous T-cell lymphomas across Australia, providing insights into possible causes

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review

Improving disease‐specific survival for patients with Sezary syndrome in the modern era of systemic therapies

Central Endocrine Complications Among Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study

Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?

Collaborators (3)

Geoff Delaney

Tomas Kron

Martine Bagot

Make your next move.